Osteomyelitis — a bone infection — can usually be resolved with surgery and antibiotics. But in some patients, the infection persists despite appropriate treatment, becoming what physicians call chronic refractory osteomyelitis. These cases are difficult to manage and carry real risk of amputation or long-term disability. Hyperbaric oxygen therapy (HBOT) is a recognized, FDA-cleared adjunctive treatment for exactly these stubborn infections.

Why Bone Infections Become Refractory

According to a clinical review published through the National Center for Biotechnology Information (NCBI), refractory osteomyelitis often develops because infected, damaged bone loses adequate blood supply, leaving the tissue chronically low on oxygen. This oxygen-poor environment does two harmful things at once: it slows the body's natural healing response, and it creates conditions where bacteria can persist even after surgery and antibiotics.

Cases are typically classified using the Cierny-Mader system, which grades osteomyelitis by both the anatomical extent of bone involvement and the patient's overall physiological ability to heal — a framework referenced consistently across the hyperbaric medicine literature when identifying which patients are likely to benefit from HBOT.

What the Research Shows

The Undersea and Hyperbaric Medical Society (UHMS), the field's leading scientific authority, states that while no large randomized controlled trials of HBOT for refractory osteomyelitis currently exist, the substantial majority of available animal studies, human case series, and non-randomized prospective trials show that adding hyperbaric oxygen to standard surgical and antibiotic management improves the ultimate rate of infection resolution. On the strength of this evidence, UHMS notes that HBOT carries an American Heart Association Class II recommendation for refractory osteomyelitis management.

The underlying mechanism has been well documented in the literature. Restoring near-normal oxygen levels to infected bone allows neutrophils — the white blood cells responsible for killing bacteria — to function properly, since these cells require adequate tissue oxygen tension to generate the bacteria-killing response, according to research summarized by UHMS. Elevated oxygen levels also support new blood vessel growth, helping deliver antibiotics more effectively to previously poorly perfused bone.

Clinical outcomes support this mechanism. A published study following patients with chronic refractory tibial osteomyelitis, all classified as advanced Cierny-Mader type III or IV, found that combining thorough surgical debridement and antibiotics with hyperbaric oxygen therapy led to safe, effective infection resolution.

What This Means for Patients

HBOT for refractory osteomyelitis is not a stand-alone cure — it works as part of a coordinated treatment plan alongside surgical debridement and targeted antibiotics, guided by infectious disease specialists, surgeons, and hyperbaric medicine physicians working together. Patients typically undergo daily sessions breathing 100% oxygen in a pressurized chamber over several weeks, in addition to their surgical and antibiotic care.

Safety and Expert Care

As a UHMS-recognized, FDA-cleared indication, HBOT for refractory osteomyelitis reflects decades of accumulated clinical experience and is often covered by Medicare and private insurance when medical necessity is documented. At Bay Area Hyperbarics, this treatment is delivered under expert care with a strong focus on patient safety throughout every session.